ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Moloney Convinces Most NCAB Members Of Virus Program Value, Shubik Only Dissenter

October 15, 1976

Senate Gives NIH Director Authority To Permit Research By Unconventional MDs

September 25, 1992

Garfinkel to Retire From ACS; Health to Succeed Him

July 20, 1990

Surgical Oncology Planners Develop NCPP research Approaches, Projects

May 24, 1974

Other Contract Concepts Approved By DCE Board

March 10, 1989

In Brief: Baker Leaves Wayne State To take Job as Deputy director, UM Cancer Center

March 23, 1994